Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > So.far.only fda
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Mole101on Jun 09, 2021 4:04pm
97 Views
Post# 33356884

RE:RE:RE:RE:RE:RE:RE:RE:So.far.only fda

RE:RE:RE:RE:RE:RE:RE:RE:So.far.only fda

last months action:
20,105,062 ($4,533,377) PMN.TO shares exchanged hands from Sun May 09 2021 to Wed Jun 09 2021.

House  Bought  Sold  Net 
House 001
Anonymous
Bought $1,260,824
Volume 5,728,977
Average $0.220
Sold $1,397,538
Volume 6,205,940
Average $0.225
Net $-136,714
Volume -476,963
 
House 002
RBC
Bought $659,475
Volume 2,989,068
Average $0.221
Sold $703,640
Volume 3,091,134
Average $0.228
Net $-44,165
Volume -102,066
 
House 007
TD Sec
Bought $419,775
Volume 1,788,429
Average $0.235
Sold $726,010
Volume 3,187,388
Average $0.228
Net $-306,235
Volume -1,398,959
 
House 009
BMO Nesbitt
Bought $268,831
Volume 1,100,600
Average $0.244
Sold $397,943
Volume 1,786,900
Average $0.223
Net $-129,112
Volume -686,300
 
House 013
Instinet
Bought $151,200
Volume 669,714
Average $0.226
Sold $197,016
Volume 838,280
Average $0.235
Net $-45,816
Volume -168,566
 
House 014
ITG
Bought $1,200
Volume 5,000
Average $0.240
Sold $16,994
Volume 84,500
Average $0.201
Net $-15,794
Volume -79,500
 
House 019
Desjardins
Bought $24,898
Volume 114,287
Average $0.218
Sold $46,598
Volume 198,992
Average $0.234
Net $-21,700
Volume -84,705
 
House 022
Fidelity
Bought $472,313
Volume 2,163,500
Average $0.218
Sold 0
Volume 0
Average 0
Net $472,313
Volume 2,163,500
 
House 033
Canaccord
Bought $202,897
Volume 840,149
Average $0.242
Sold $206,682
Volume 848,830
Average $0.243
Net $-3,785
Volume -8,681
 
House 036
Latimer
Bought $588
Volume 2,731
Average $0.215
Sold $1,450
Volume 5,956
Average $0.243
Net $-862
Volume -3,225
 
House 039
Merrill Lynch
Bought $23,287
Volume 90,603
Average $0.257
Sold $646
Volume 2,996
Average $0.216
Net $22,641
Volume 87,607
 
House 053
Morgan Stanley
Bought $66,508
Volume 298,623
Average $0.223
Sold $24,762
Volume 134,195
Average $0.185
Net $41,746
Volume 164,428
 
House 055
Velocity
Bought $1,626
Volume 6,574
Average $0.247
Sold 0
Volume 0
Average 0
Net $1,626
Volume 6,574
 
House 057
Interactive
Bought $541
Volume 2,540
Average $0.213
Sold $1,657
Volume 7,750
Average $0.214
Net $-1,116
Volume -5,210
 
House 059
PI
Bought 0
Volume 0
Average 0
Sold $2,940
Volume 14,000
Average $0.210
Net $-2,940
Volume -14,000
 
House 062
Haywood
Bought $2,300
Volume 10,000
Average $0.230
Sold 0
Volume 0
Average 0
Net $2,300
Volume 10,000
 
House 065
Goldman
Bought $24,351
Volume 97,500
Average $0.250
Sold 0
Volume 0
Average 0
Net $24,351
Volume 97,500
 
House 068
Leede
Bought 0
Volume 0
Average 0
Sold $19,200
Volume 80,000
Average $0.240
Net $-19,200
Volume -80,000
 
House 070
Manulife
Bought $7,500
Volume 30,000
Average $0.250
Sold 0
Volume 0
Average 0
Net $7,500
Volume 30,000
 
House 079
CIBC
Bought $162,984
Volume 803,330
Average $0.203
Sold $178,696
Volume 762,299
Average $0.234
Net $-15,712
Volume 41,031
 
House 080
National Bank
Bought $297,708
Volume 1,291,681
Average $0.230
Sold $325,445
Volume 1,623,137
Average $0.201
Net $-27,737
Volume -331,456
 
House 083
Mackie
Bought $288,445
Volume 1,194,000
Average $0.242
Sold $3,500
Volume 20,000
Average $0.175
Net $284,945
Volume 1,174,000
 
House 085
Scotia
Bought $113,228
Volume 503,971
Average $0.225
Sold $109,560
Volume 484,479
Average $0.226
Net $3,668
Volume 19,492
 
House 088
Credential
Bought $33,798
Volume 159,900
Average $0.211
Sold $18,216
Volume 76,814
Average $0.237
Net $15,582
Volume 83,086
 
House 089
Raymond James
Bought $10,350
Volume 47,212
Average $0.219
Sold $25,341
Volume 128,547
Average $0.197
Net $-14,991
Volume -81,335
 
House 124
Questrade
Bought $31,344
Volume 136,120
Average $0.230
Sold $46,586
Volume 189,942
Average $0.245
Net $-15,242
Volume -53,822
 
House 143
Pershing
Bought $7,406
Volume 30,553
Average $0.242
 


Mole101 wrote:

We had NRs for the last couple of weeks on Thursdays , Sp holding and couple of unusual houses loading .. maybe more news to come...

 

Gbathat wrote: Agreed. I've been in buy the dips mode for the last year but I don't plan on selling any soon, even though I am up 70% now.  I'll clear my original investment at the right time as the developments occur. Too much potential upside here.

I've been impressed with the HODLing so far. We have like minded investors on this one. Because it is not a typical penny stock.

 

 

 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities